The introduction of Sofosbuvir has significantly advanced the treatment of chronic Hepatitis C virus (HCV) infection, offering high cure rates and improved tolerability. NINGBO INNO PHARMCHEM CO.,LTD. emphasizes the clinical efficacy and safety of this vital medication, providing high-quality APIs to support its widespread use.

Clinical trials have consistently demonstrated the impressive efficacy of Sofosbuvir, particularly when used in combination therapies. For patients with genotypes 1, 4, 5, or 6, a 12-week regimen of Sofosbuvir with peginterferon alfa and ribavirin has shown high sustained virologic response (SVR12) rates, often exceeding 90%. Similarly, for genotypes 2 and 3, Sofosbuvir combined with ribavirin for 12 or 24 weeks (depending on prior treatment history and cirrhosis status) has yielded excellent SVR12 outcomes.

The safety profile of Sofosbuvir is generally favorable. Most adverse events reported in clinical trials are mild to moderate, including fatigue, headache, nausea, and insomnia. However, important safety considerations include the risk of HBV reactivation in coinfected patients and potential drug interactions, particularly with P-gp inducers. NINGBO INNO PHARMCHEM CO.,LTD. recognizes the critical importance of these safety aspects and ensures that its Sofosbuvir products meet stringent quality standards.

For patients with specific conditions, such as those awaiting liver transplantation, Sofosbuvir combined with ribavirin can be used to prevent post-transplant HCV reinfection. The drug's approval for pediatric use in patients aged 3 years and older further broadens its clinical application. The development of interferon-free regimens, where applicable, further enhances the drug's tolerability and patient convenience.

NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supporting the global effort to combat Hepatitis C by providing reliable access to Sofosbuvir. Our commitment to quality ensures that healthcare professionals can confidently prescribe this effective and safe antiviral agent, contributing to better health outcomes for patients worldwide.